ACSL5 and lung cancer: We analyzed the potential influences of the selected target gene ACSL5 in patient survival and found that ACSL5‐high‐expressing patients in lung cancer tissues and ADC tissues had significantly better 10‐year overall survival rates than that of the patient with low expression (Figure 3D, p < .01, respectively).